HealthDay News – Guidelines for the treatment of people at or at risk for sexually transmitted infections (STIs) have been updated according to a report published in the July 23 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report has been published.
Kimberly A. Workowski, MD, of the CDC in Atlanta, and colleagues updated guidelines for the treatment of those with or at risk of STIs after consulting with professionals who have knowledge of the STIs.
The guidelines contain updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis. For pelvic inflammatory disease, metronidazole has been added to the recommended treatment regimen. For bacterial vaginosis, recommended therapies include oral metronidazole, metronidazole gel, or clindamycin cream, and alternative therapies include oral clindamycin, clindamycin ova, secnidazole, and tinidazole. The recommendations for the management of Mycoplasma genitalium have been updated, with recommended treatment regimens varying if resistance tests are available or not. Recommendations and advisory messages for vaccination against human papillomavirus have been updated. Extended risk factors for syphilis testing were included in pregnant women. A one-time test is recommended if you have hepatitis C infection. For men who have sex with men, the sexual assault assessment recommendations have been updated to include ceftriaxone in a single dose and doxycycline twice a day for seven days. A two-stage test is recommended for the serological diagnosis of herpes simplex genital virus.
This report “should be viewed as a source of clinical guidelines rather than binding standards,” the authors write. “Healthcare providers should always consider each person’s clinical circumstances in the context of local disease prevalence.”
Several authors have disclosed financial ties to the biopharmaceutical, medical device, and medical technology industries.
Summary / full text